Olanib 50 (Olaparib) 50 mg Capsules

Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced cancers:

• 🔹 Ovarian Cancer: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• 🔹 Therapy Goal: To maintain remission after response to platinum-based chemotherapy.

Packaging: 50 mg capsules.

⚠️ ADMINISTRATION PROTOCOL (Specific for Capsules):

• Total Daily Dose: 800 mg (400 mg twice daily).
• Per Dose: Take 8 capsules (50 mg each) at once, twice daily.
• Total Pills: 16 capsules per day.
• Timing & Food: Take on an empty stomach. Take at least 1 hour after a meal, and do not eat for 2 hours after taking the capsules.
• Administration: Swallow whole. Do not chew, dissolve, or open the capsules.

• Hypersensitivity to Olaparib.
• Pregnancy and breastfeeding (embryo-fetal toxicity).
• Moderate to severe hepatic or renal impairment.

Common adverse reactions include:

• 🩸 Hematological: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood counts are recommended.
• 📉 Gastrointestinal: Nausea, vomiting (very common), diarrhea, loss of appetite, dysgeusia (taste distortion).
• 🌀 Physical: Fatigue (asthenia), headache, dizziness.
• Patients should be monitored for signs of blood toxicity (pale skin, shortness of breath).